X4 Pharmaceuticals Inc. (XFOR)
NASDAQ (CM) NASDAQ (CM) Primary Summary
X4 Pharmaceuticals: Betting On Mavorixafor For Chronic Neutropenia
X4 Pharmaceuticals is a single-asset biotech built around Mavorixafor. This is approved for WHIM in the US, and the next step is a label expansion for CN. XFOR's 4WARD Phase 3 trial in CN will be key. This could unlock a sizeable TAM across 15,000 patients with moderate-to-severe symptoms. Mavorixafor's initial Phase 2 data showed that once-daily oral doses helped with ANC and may reduce G-CSF exposure.
X4 Pharmaceuticals (XFOR) Reports Q3 Loss, Misses Revenue Estimates
X4 Pharmaceuticals (XFOR) came out with a quarterly loss of $0.69 per share versus the Zacks Consensus Estimate of a loss of $0.79. This compares to a loss of $5.41 per share a year ago.
X4 Pharmaceuticals (XFOR) Upgraded to Strong Buy: What Does It Mean for the Stock?
X4 Pharmaceuticals (XFOR) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
X4 Pharmaceuticals Inc. (XFOR) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has X4 Pharmaceuticals Inc. ever had a stock split?
X4 Pharmaceuticals Inc. Profile
| Biotechnology Industry | Healthcare Sector | Adam R. Craig CEO | NASDAQ (CM) Exchange | 98420X202 CUSIP |
| US Country | 143 Employees | - Last Dividend | 14 Mar 2019 Last Split | 16 Nov 2017 IPO Date |
Overview
X4 Pharmaceuticals, Inc. is a biopharmaceutical company engaged in late-stage clinical development, primarily focusing on crafting innovative therapeutics for the treatment of rare diseases. Positioned at the forefront of biomedical research, the company leverages its expertise in the domain of small molecule inhibitors, with a specific concentration on targeting the C-X-C chemokine receptor type 4 (CXCR4). Operating from its headquarters in Boston, Massachusetts, X4 Pharmaceuticals strives to address the unmet medical needs of patients suffering from complex conditions that are often overlooked in the broader pharmaceutical landscape. Through a steadfast commitment to scientific excellence and patient-centric research, the company endeavors to break new ground in the field of rare disease treatment.
Products and Services
1. Mavorixafor (Lead Product Candidate)
Mavorixafor stands at the forefront of X4 Pharmaceuticals' pipeline as a leading product candidate. It is a novel small molecule inhibitor targeting the chemokine receptor CXCR4. Currently in a Phase III clinical trial, mavorixafor is being evaluated for its efficacy in treating patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome (WHIM). Additionally, it is undergoing a Phase Ib clinical trial aimed at addressing chronic neutropenia and Waldenström's macroglobulinemia. This diverse application spectrum underscores mavorixafor's potential in transforming the therapeutic landscape for patients afflicted by these rare conditions.
2. X4P-002 (Research Program)
X4P-002 represents another critical component of X4 Pharmaceuticals’ product pipeline, developed as a CXCR4 antagonist for the potential treatment of brain cancers. By targeting specific pathways associated with tumor growth and spread, X4P-002 embodies the company's dedication to expanding the current treatment paradigms for cancer patients, especially those battling aggressive and difficult-to-treat brain malignancies.
3. X4P-003 (Research Program)
Further extending its research into the therapeutic potential of CXCR4 antagonism, X4 Pharmaceuticals is developing X4P-003 for treating a range of CXCR4 disorders and primary immunodeficiencies. This program emphasizes the company's commitment to harnessing its platform’s full potential in addressing various diseases tied to the CXCR4 receptor, promising new hope for patients with limited treatment options.
In addition to its robust internal pipeline, X4 Pharmaceuticals has established a strategic license agreement with Abbisko Therapeutics Co., Ltd. This partnership facilitates the development, manufacture, and commercialization of mavorixafor in combination with checkpoint inhibitors or other therapeutic agents across oncology indications, further amplifying the impact of X4 Pharmaceuticals’ innovative approach to drug development.
Contact Information
